CL2014002183A1 - Polipeptidos de factor ix modificado con ctp; polinucleotido que lo codifica; composicion que lo comprende; usos y metodo para tratar hemofilia; factores de coagulacion modificados con ctp y sus usos. - Google Patents

Polipeptidos de factor ix modificado con ctp; polinucleotido que lo codifica; composicion que lo comprende; usos y metodo para tratar hemofilia; factores de coagulacion modificados con ctp y sus usos.

Info

Publication number
CL2014002183A1
CL2014002183A1 CL2014002183A CL2014002183A CL2014002183A1 CL 2014002183 A1 CL2014002183 A1 CL 2014002183A1 CL 2014002183 A CL2014002183 A CL 2014002183A CL 2014002183 A CL2014002183 A CL 2014002183A CL 2014002183 A1 CL2014002183 A1 CL 2014002183A1
Authority
CL
Chile
Prior art keywords
ctp
modified
polynucleotide
polypeptides
encodes
Prior art date
Application number
CL2014002183A
Other languages
English (en)
Inventor
Udi Eyal Fima
Gili Hart
Original Assignee
Opko Biolog Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed by Opko Biolog Ltd filed Critical Opko Biolog Ltd
Publication of CL2014002183A1 publication Critical patent/CL2014002183A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
CL2014002183A 2012-02-14 2014-08-14 Polipeptidos de factor ix modificado con ctp; polinucleotido que lo codifica; composicion que lo comprende; usos y metodo para tratar hemofilia; factores de coagulacion modificados con ctp y sus usos. CL2014002183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same

Publications (1)

Publication Number Publication Date
CL2014002183A1 true CL2014002183A1 (es) 2015-01-09

Family

ID=48983616

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014002183A CL2014002183A1 (es) 2012-02-14 2014-08-14 Polipeptidos de factor ix modificado con ctp; polinucleotido que lo codifica; composicion que lo comprende; usos y metodo para tratar hemofilia; factores de coagulacion modificados con ctp y sus usos.
CL2017002233A CL2017002233A1 (es) 2012-02-14 2017-09-04 Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017002233A CL2017002233A1 (es) 2012-02-14 2017-09-04 Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.

Country Status (22)

Country Link
EP (3) EP3326642B1 (es)
JP (2) JP6242819B2 (es)
KR (3) KR102310704B1 (es)
CN (2) CN104427994A (es)
AU (3) AU2013219935B2 (es)
BR (1) BR122021004014B1 (es)
CA (1) CA2870621C (es)
CL (2) CL2014002183A1 (es)
CO (1) CO7131365A2 (es)
DK (2) DK3326642T3 (es)
EA (2) EA028578B1 (es)
ES (2) ES2665319T3 (es)
HK (1) HK1205460A1 (es)
HU (1) HUE053068T2 (es)
IL (2) IL264959B (es)
MX (3) MX362446B (es)
MY (1) MY172539A (es)
NO (1) NO2920022T3 (es)
PE (1) PE20142290A1 (es)
PL (1) PL3326642T3 (es)
SG (1) SG11201404836QA (es)
WO (1) WO2013121416A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745680B2 (en) 2015-08-03 2020-08-18 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JP6242819B2 (ja) 2012-02-14 2017-12-06 オプコ バイオロジクス リミテッド 長時間作用型凝固因子およびその生成方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
SG11201704706RA (en) 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
WO2016203482A2 (en) * 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
BR112019000610A2 (pt) * 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技(上海)有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技(上海)有限公司 双特异性抗体及其制备方法与用途
JP7023925B2 (ja) 2017-03-08 2022-02-22 テイ・エス テック株式会社 乗物用シート
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2053864C (en) 1989-02-21 2001-11-20 Irving Boime Modified forms of reproductive hormones
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
KR20110039348A (ko) * 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
JP6242819B2 (ja) 2012-02-14 2017-12-06 オプコ バイオロジクス リミテッド 長時間作用型凝固因子およびその生成方法
ES2882890T3 (es) * 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745680B2 (en) 2015-08-03 2020-08-18 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same

Also Published As

Publication number Publication date
ES2665319T3 (es) 2018-04-25
KR20210125595A (ko) 2021-10-18
BR112014020198A2 (pt) 2018-05-15
EP2822576A4 (en) 2015-11-25
MX2014009910A (es) 2015-09-28
JP6510002B2 (ja) 2019-05-08
EA201491519A1 (ru) 2014-12-30
CA2870621A1 (en) 2013-08-22
HK1205460A1 (en) 2015-12-18
EA028578B1 (ru) 2017-12-29
EA201790960A3 (ru) 2018-01-31
AU2016202829A1 (en) 2016-05-19
EP2822576A1 (en) 2015-01-14
EP3791890A1 (en) 2021-03-17
JP2018065815A (ja) 2018-04-26
MX362446B (es) 2019-01-18
CN109535245A (zh) 2019-03-29
DK3326642T3 (da) 2021-02-22
MX2019000708A (es) 2020-09-02
WO2013121416A1 (en) 2013-08-22
KR20140134673A (ko) 2014-11-24
SG11201404836QA (en) 2014-12-30
KR20200063274A (ko) 2020-06-04
MY172539A (en) 2019-11-30
AU2013219935B2 (en) 2016-02-04
CA2870621C (en) 2022-08-09
HUE053068T2 (hu) 2021-06-28
IL282121B (en) 2022-06-01
AU2017219044A1 (en) 2017-09-14
AU2013219935A1 (en) 2014-09-25
EP3326642A1 (en) 2018-05-30
PE20142290A1 (es) 2015-01-15
AU2016202829B2 (en) 2017-05-25
EA201790960A2 (ru) 2017-09-29
KR102310704B1 (ko) 2021-10-08
BR122021004014B1 (pt) 2022-12-27
CL2017002233A1 (es) 2018-05-11
DK2822576T3 (en) 2018-04-16
KR102118729B1 (ko) 2020-06-05
IL264959B (en) 2021-08-31
EP3326642B1 (en) 2020-11-25
CO7131365A2 (es) 2014-12-01
CN104427994A (zh) 2015-03-18
IL282121A (en) 2021-05-31
EP2822576B1 (en) 2018-01-10
NO2920022T3 (es) 2018-06-09
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
ES2855133T3 (es) 2021-09-23
JP2015508771A (ja) 2015-03-23
AU2017219044B2 (en) 2019-05-30
JP6242819B2 (ja) 2017-12-06
MX2022008807A (es) 2022-08-11

Similar Documents

Publication Publication Date Title
CL2014002183A1 (es) Polipeptidos de factor ix modificado con ctp; polinucleotido que lo codifica; composicion que lo comprende; usos y metodo para tratar hemofilia; factores de coagulacion modificados con ctp y sus usos.
DK3087024T3 (da) Drikkevarevaredispenser og fremgangsmåde til at blande en eller flere drikkevarekomponenter med mindst en kulsyreholdig væske
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
DK3212208T3 (da) Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
DK3303117T3 (da) Sikkerhedsforbedringer til uv-stråling i vandapplikationer
CL2015002801A1 (es) Métodos para tratar la osteogénesis imperfecta.
DK2967040T3 (da) Biocidholdig sammensætning og fremgangsmåde til behandling af vand eller overflader i kontakt med vand
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
BR112017000358A2 (pt) incorporação de agentes biológicos em fertilizantes
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
GB201621394D0 (en) Improvements in and relating to waste treatment
BR112015003640A2 (pt) método de ancoragem de navio e disposição para obtenção do método
BR112015002531A2 (pt) composição, método de tratamento de hipersensibilidade e uso de carbonato de cálcio.
GB201509942D0 (en) Improvements in or relating to railway platforms
BR112015002551A2 (pt) composição, método de tratamento para hipersensibilidade e uso do carbonato de cálcio particulado.
CL2018001010A1 (es) Componentes y métodos para separar líquidos inmiscibles.
DK3119386T3 (da) Sammensætning til anvendelse ved behandling af intervertebral diskus-relateret smerte.
GB201508478D0 (en) Improvements in or relating to level switches
GB201507896D0 (en) Improvements in or relating to level switches
ZA201700174B (en) Bar composition and methods for maintaining enhanced lather in presence of water with high electrolyte concentration
GB201513464D0 (en) Improvements in and relating to road guarding lamps
FR3021844B1 (fr) Composition de sorbitol de faible friabilite
GB2532750B (en) Improvements in and relating to emergency beacon assemblies
DE112015003477A5 (de) Mobiles Gerät, insbesondere zur Verhinderung von Thrombosen